Stagaire bio-informaticien(ne)
Stage · Stage M2
· 6 mois
Bac+5 / Master
Centre de Recherche sur l'Inflammation, U1149. · Clichy (France)
682.5 euros mensuel
Date de prise de poste : 4 janvier 2027
Mots-Clés
multiomic
hepatocellular carcinoma
microenvironment
transcriptomics
proteomics
epigenomics
histology
Description
Context: Hepatocellular carcinoma (HCC), the most common primary liver tumor, is aggressive, with a 5-year survival around 20%. The 2020 approval of atezolizumab (immunotherapy) plus bevacizumab (anti-angiogenic) was a major advance for a disease long refractory to treatment, but response rates remain low (27% vs 11% for the sorafenib control arm). Biomarkers of treatment response are therefore urgently needed.
Our team recently identified a histological biomarker, the “Vessels Encapsulating Tumor Clusters” (VETC) phenotype, in which vascular cells strikingly wrap small clusters of tumor cells (Figure 1). Although VETC normally carries a poor prognosis, our data show that it responds well to atezolizumab/bevacizumab but poorly to immunotherapy alone. Its biology remains poorly understood.
Goal: The intern will mine multiomic data to better characterize VETC+ HCC tumors and understand their specific biology. The candidate is thus expected to analyze multiomic data from the TCGA-LIHC project, a cohort of 196 HCC cases with full multiomic characterization (whole exome sequencing, DNA methylation, RNA, miRNA, and proteomic expression). VETC statuses will be assessed by expert medical doctors in the team. A highly successful candidate would be offered to extend the analysis with computer-vision models accounting for tumor spatial heterogeneity.
Offre publiée le 17 novembre 2026, affichage jusqu'au 15 décembre 2026